Evaluation of Gemtuzumab Ozogamicin and Anthracycline Dosing for Favorable Risk Acute Myeloid Leukemia

Gemtuzumab ozogamicin (GO) is a CD33-targeting antibody-drug conjugate approved for the treatment of CD33-positive de novo and relapsed and refractory acute myeloid leukemia (AML). Subset analyses have demonstrated improved clinical outcomes in patients with favorable-risk disease. It is unclear whe...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	European journal of haematology 2024-11
Hauptverfasser:	Mort, Joseph F, Brighton, David, DiBenedetto, Samantha, Wells, Leah, Clark, Stephen M, Reid, Justin, Patel, Imari, Jackson, Clayton, Yelvington, Bradley, Miller, Ryan, Perciavalle, Matthew, Walsh, Katherine, Wolfe, Heather, Locke, Susan C, Zeidner, Joshua F, Duong, Vu H, Reed, Daniel R, Dholaria, Bhagirathbhai, LeBlanc, Thomas W, Keng, Michael, Horton, Bethany, El Chaer, Firas
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!